Oxiracetam
A water-soluble racetam studied mainly in older adults with cognitive impairment. It is sometimes described as more 'stimulating' than piracetam. Human data exist but are dated and limited, and it is not approved in most Western markets.
01 Overview
Oxiracetam is a hydroxylated derivative of piracetam investigated in the 1980s-90s for dementia and cognitive impairment, with several small European trials. It remains available in a few countries but is not approved in the US or UK.
Reported effects centre on attention and memory in impaired populations, with a reputation among users for a mildly stimulating quality. Evidence in healthy adults is largely absent, and its safety profile is broadly benign in the studies conducted.
02 Mechanism
Modulates cholinergic and glutamatergic (AMPA/NMDA) transmission and may enhance long-term potentiation; exact mechanism is not fully established.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Typical | 800–2400 mg/day | Oral | Usually split into 2 doses; some avoid late dosing due to alerting effect. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Attention / memory supportOlder trials in dementia reported modest improvements on cognitive scales. | Small, in impaired populations | Observational | |
| Mild alerting effectUsers often describe a subtly stimulating quality. | Small | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Insomnia / restlessnessTrouble sleeping if taken late in the day. | Mild | Uncommon | Anecdotal | |
| HeadacheOccasional headache reported by users. | Mild | Uncommon | Anecdotal |